{
    "@graph": [
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1769859519",
            "@type": "bibo:Thesis",
            "P1053": "1 Online-Ressource",
            "http://purl.org/dc/elements/1.1/contributor": [
                "Eilers, Martin",
                "Gessler, Manfred"
            ],
            "creator": "R\u00f6schert, Isabelle",
            "identifier": [
                "(firstid)DNB:1239052804",
                "(doi)10.25972/OPUS-24303",
                "(ppn)1769859519"
            ],
            "publisher": "Universit\u00e4t W\u00fcrzburg",
            "subject": [
                "(classificationName=linseach:mapping)meda",
                "(classificationName=ddc-dbn)570",
                "(classificationName=ddc-dbn)610",
                "(classificationName=ddc)618.92",
                "(classificationName=linseach:mapping)bio"
            ],
            "title": "Aurora-A prevents transcription-replication conflicts in MYCN-amplified neuroblastoma",
            "abstract": "Neuroblastoma is the most abundant, solid, extracranial tumor in early childhood and the leading cause of cancer-related childhood deaths worldwide. Patients with high-risk neuroblastoma often show MYCN-amplification and elevated levels of Aurora-A. They have a low overall survival and despite multimodal therapy options a poor therapeutic prognosis. MYCN-amplified neuroblastoma cells depend on Aurora-A functionality. Aurora-A stabilizes MYCN and prevents it from proteasomal degradation by competing with the E3 ligase SCFFBXW7. Interaction between Aurora-A and MYCN can be observed only in S phase of the cell cycle and activation of Aurora-A can be induced by MYCN in vitro. These findings suggest the existence of a profound interconnection between Aurora-A and MYCN in S phase. Nevertheless, the details remain elusive and were investigated in this study. Fractionation experiments show that Aurora-A is recruited to chromatin in S phase in a MYCN-dependent manner. Albeit being unphosphorylated on the activating T288 residue, Aurora-A kinase activity was still present in S phase and several putative, novel targets were identified by phosphoproteomic analysis. Particularly, eight phosphosites dependent on MYCN-activated Aurora-A were identified. Additionally, phosphorylation of serine 10 on histone 3 was verified as a target of this complex in S phase. ChIP-sequencing experiments reveal that Aurora-A regulates transcription elongation as well as histone H3.3 variant incorporation in S phase. 4sU-sequencing as well as immunoblotting demonstrated that Aurora-A activity impacts splicing. PLA measurements between the transcription and replication machinery revealed that Aurora-A prevents the formation of transcription-replication conflicts, which activate of kinase ATR. Aurora-A inhibitors are already used to treat neuroblastoma but display dose-limiting toxicity. To further improve Aurora-A based therapies, we investigated whether low doses of Aurora-A inhibitor combined with ATR inhibitor could increase the efficacy of the treatment albeit reducing toxicity. The study shows that the combination of both drugs leads to a reduction in cell growth as well as an increase in apoptosis in MYCN-amplified neuroblastoma cells, which is not observable in MYCN non-amplified neuroblastoma cells. This new approach was also tested by a collaboration partner in vivo resulting in a decrease in tumor burden, an increase in overall survival and a cure of 25% of TH-MYCN mice. These findings indicate indeed a therapeutic window for targeting MYCN-amplified neuroblastoma. ; Das Neuroblastom ist der h\u00e4ufigste, solide, extrakranielle Tumor der fr\u00fchesten Kindheit und die h\u00e4ufigste mit Krebs verbundene Todesursache von Kleinkindern weltweit. Patienten mit geringerer \u00dcberlebenswahrscheinlichkeit und schlechterer Therapieprognose zeigen oft eine MYCN-Amplifikation und erh\u00f6hte Mengen von Aurora-A. Aurora-A ist eine Serin/Threonin-Protein Kinase, die wichtige mitotische Prozesse reguliert. Aurora-A stabilisiert MYCN und verhindert dadurch den proteasomalen Abbau von MYCN. Die Interaktion zwischen Aurora-A und MYCN ist S Phasen-spezifisch und MYCN ist in vitro in der Lage, durch seine Bindung Aurora-A zu aktivieren. Die Funktionen und Prozesse, die von Aurora-A in der S Phase reguliert werden, sind noch nicht hinreichend untersucht und daher Gegenstand dieser Dissertation. Zell-Fraktionierungen zeigen, dass Aurora-A in der S Phase in einer MYCN-abh\u00e4ngigen Weise an das Chromatin gebunden ist. Phosphoproteom-Analysen mittels Massenspektrometrie identifizierten zahlreiche neue Substrate von Aurora-A, sowie acht Substrate von MYCN-aktiviertem Aurora-A. Zus\u00e4tzlich konnte gezeigt werden, dass Histon 3 Serin 10 von Aurora-A in Abh\u00e4ngigkeit von MYCN in S Phase phosphoryliert wird. ChIP-Sequenzierungen zeigen, dass Aurora-A die Elongation der Transkription und den Einbau der Histone Variante H3.3 in S Phase beeinflusst. 4sU-Sequenzierung sowie Immunoblots zeigen einen Zusammenhang zwischen der Aktivit\u00e4t von Aurora-A und dem Splei\u00dfosom in der S Phase. Zus\u00e4tzlich konnte mittels PLA nachgewiesen werden, dass Aurora-A die Entstehung von Transkriptions-Replikationskonflikten verhindert, die andernfalls die Kinase ATR aktivieren w\u00fcrden. Aurora-A Inhibitoren wurden unter anderem zur Therapie von Neuroblastomen eingesetzt, allerdings ist die Dosis des Aurora-A Inhibitors durch die hohe Toxizit\u00e4t limitiert, was die Effizienz der Therapie stark beeintr\u00e4chtigt. Daher wurde untersucht, ob die gleichzeitige Gabe von geringeren Mengen Aurora-A Inhibitor in Kombination mit einem ATR Inhibitor zur Therapie geeignet ist. In vitro konnte gezeigt werden, dass die Kombination beider Inhibitoren das Zellwachstum reduziert und das MYCN-amplifizierte Zellen im Vergleich zu MYCN nicht-amplifizierten Zellen verst\u00e4rkt durch Apoptose sterben. Durch einen Kollaborationspartner konnte die Kombination der beiden Inhibitoren an M\u00e4usen getestet werden. Die mit der Kombination behandelten M\u00e4use, zeigen ein deutlich reduziertes Tumorwachstum, sowie l\u00e4ngeres \u00dcberleben. Somit stellt diese Kombination ein therapeutisches Fenster dar und k\u00f6nnte zur Behandlung von Neuroblastompatienten genutzt werden.",
            "alternative": "Aurora-A verhindert Transkriptions-Replikationskonflikte in MYCN-amplifizierten Neuroblastomen",
            "contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": [
                "(collectioncode)GBV-ODiss",
                "(collectioncode)GBV-BASE-ODISS"
            ],
            "issued": "2021",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "open access",
            "medium": "rda:termList/RDACarrierType/1018",
            "isLike": "doi:10.25972/OPUS-24303",
            "P60163": "W\u00fcrzburg"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "license": "http://purl.org/dc/terms/license",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "issued": "http://purl.org/dc/terms/issued",
        "contributor": "http://purl.org/dc/terms/contributor",
        "abstract": "http://purl.org/dc/terms/abstract",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "alternative": "http://purl.org/dc/terms/alternative",
        "title": "http://purl.org/dc/elements/1.1/title",
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}